ChiCTR2100048572 版本V1.1 版本创建时间2022/03/20 04:29:08 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100048572 

最近更新日期:

Date of Last Refreshed on:

2022-02-24 19:54:13 

注册时间:

Date of Registration:

2021-07-11 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

环孢素A在不明原因反复着床失败患者胚胎移植中的研究

Public title:

Application of cyclosporin A in patients with unexplained repeated implantation failure in embryo transfer

注册题目简写:

English Acronym:

研究课题的正式科学名称:

环孢素A在不明原因反复着床失败患者胚胎移植中的研究

Scientific title:

Application of cyclosporin A in patients with unexplained repeated implantation failure in embryo transfer

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

龚衍 

研究负责人:

龚衍 

Applicant:

Gong Yan 

Study leader:

Gong Yan 

申请注册联系人电话:

Applicant telephone:

+86 15208393996

研究负责人电话:

Study leader's telephone:

+86 15208393996

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

gongyan_496181657@qq.com

研究负责人电子邮件:

Study leader's E-mail:

gongyan_496181657@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

四川省成都市武侯区晋阳路沙堰西二街290号

研究负责人通讯地址:

四川省成都市武侯区晋阳路沙堰西二街290号

Applicant address:

290 Second Shayan Street West, Wuhou District, Chengdu, Sichuan, China

Study leader's address:

290 Second Shayan Street West, Wuhou District, Chengdu, Sichuan, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

四川省妇女儿童医院

Applicant's institution:

Sichuan Provincial Hospital for Woman and Children

研究负责人所在单位:

四川省妇女儿童医院

Affiliation of the Leader:

Sichuan Provincial Hospital for Woman and Children

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

20210617

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

四川省妇女儿童医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Sichuan Provincial Hospital for Woman and Children

伦理委员会批准日期:

Date of approved by ethic committee:

2021-06-17 00:00:00

伦理委员会联系人:

常姝蕾

Contact Name of the ethic committee:

Chang Shulei

伦理委员会联系地址:

四川省成都市武侯区晋阳路沙堰西二街290号

Contact Address of the ethic committee:

290 Second Shayan Street West, Wuhou District, Chengdu, Sichuan, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 19934540615

伦理委员会联系人邮箱:

Contact email of the ethic committee:

350179076@qq.com

研究实施负责(组长)单位:

四川省妇女儿童医院

Primary sponsor:

Sichuan Provincial Hospital for Woman and Children

研究实施负责(组长)单位地址:

四川省武侯区晋阳路沙堰西二街290号

Primary sponsor's address:

290 Second Shayan Street West, Wuhou District, Chengdu, Sichuan, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川

市(区县):

成都

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

四川省妇女儿童医院

具体地址:

武侯区晋阳路沙堰西二街290号

Institution
hospital:

Sichuan Provincial Hospital For Woman and Children

Address:

290 Second Shayan Street West, Wuhou District

经费或物资来源:

Source(s) of funding:

None

Target disease:

unexplained repeated implantation failure

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

主要目的:提高不明原因反复着床失败患者再次胚胎移植临床妊娠率。  

Objectives of Study:

Main purpose: To improve the clinical pregnancy rate in patients with unexplained repeated implantation failure.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.不明原因反复着床失败患者;
2.20-40岁。

Inclusion criteria

1.Patients who unexplained repeated implantaion failure in our reproductive center;
2.Aged 20 to 40 years.

排除标准:

1.赠卵周期,卵子冷冻复苏后卵胞浆内单精子注射(intracytoplasmic sperm injection, ICSI)周期;
2.具有FIR病因者;
3.吸烟、酗酒者;
4.体质量指数(body mass index, BMI)≥ 28 kg/m2或 < 18 kg/m2;
5.环孢素过敏者。

Exclusion criteria:

1. Donor oocyte cycles; ICSI cycle after freeze-thawed oocyte;
2. Patients with the reasons of RIF;
3. patients with the habit of smoking or drinking alcohol;
4. BMI>= 30 kg/m2, < 18 kg/m2;
5. Patients with cyclosporin A contraindications;

研究实施时间:

Study execute time:

From 2021-07-15 00:00:00 To 1990-01-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-07-15 00:00:00 To 2023-12-01 00:00:00  

干预措施:

Interventions:

组别:

试验组

样本量:

100

Group:

Experimental group

Sample size:

干预措施:

使用环孢素

干预措施代码:

Intervention:

application with cyclosporin A

Intervention code:

组别:

对照组

样本量:

100

Group:

Control group

Sample size:

干预措施:

干预措施代码:

Intervention:

No

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

四川 

市(区县):

成都 

Country:

China 

Province:

Sichuan 

City:

Chengdu 

单位(医院):

四川省妇女儿童医院 

单位级别:

三级甲等 

Institution
hospital:

Sichuan Provincial Hospital for Woman and Children

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

临床妊娠率

指标类型:

主要指标

Outcome:

clinical pregnancy rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胚胎着床率

指标类型:

次要指标

Outcome:

embryo implantation rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

No

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 20 years
最大 Max age 40 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

no

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

no

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

我院生殖医学中心微信平台

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

WeChat platform of reproductive center in our hospital

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

电子采集管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Electronic Data Capture

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-07-11 00:48:32